Rituximab Completed Phase 1 / 2 Trials for Intraocular Lymphoma / Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Lymphomatous Involvement of Non-Cutaneous Extranodal Site / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Hepatosplenic T-Cell Lymphoma / Splenic Marginal Zone Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Waldenström's Macroglobulinemia (WM) / Recurrent Marginal Zone Lymphoma / Chronic Lymphocytic Leukemia (CLL) - Refractory / Recurrent Adult Acute Lymphoblastic Leukemia / Refractory Plasma Cell Myeloma / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Adult Immunoblastic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Refractory Hairy Cell Leukemia / Testicular Lymphoma / Recurrent Adult Burkitt Lymphoma / Adult B Acute Lymphoblastic Leukemia / Recurrent Small Lymphocytic Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Chronic Lymphocytic Leukaemia (CLL) / Recurrent Mycosis Fungoides and Sezary Syndrome / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Adult Solid Neoplasm / Recurrent Adult T-Cell Leukemia/Lymphoma / Nodal Marginal Zone Lymphoma / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Anaplastic Large Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Small Intestinal Lymphoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT00366418Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia
NCT01292603A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia
NCT00330252Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
NCT00868413Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT01185262Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia